Antibody-targeted nanoparticles for cancer therapy - PubMed (original) (raw)

Review

Antibody-targeted nanoparticles for cancer therapy

Francois Fay et al. Immunotherapy. 2011 Mar.

Abstract

In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, in particular antibodies. Antibody-nanoparticle conjugates have the potential to elicit effective targeting and release of therapeutic targets at the disease site, while minimizing off-target side effects caused by dosing of normal tissues. This article provides an overview of various antibody-conjugated nanoparticle strategies, focusing on the rationale of cell-surface receptors targeted and their potential clinical application.

PubMed Disclaimer

Similar articles

• [Targeted nanomedicine in diagnostics and therapy of neurological diseases].
  Bertalan F, László B, Attila V. Bertalan F, et al. Ideggyogy Sz. 2013 May 30;66(5-6):155-63. Ideggyogy Sz. 2013. PMID: 23909015 Review. Hungarian.
• Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring.
  Namiki Y, Fuchigami T, Tada N, Kawamura R, Matsunuma S, Kitamoto Y, Nakagawa M. Namiki Y, et al. Acc Chem Res. 2011 Oct 18;44(10):1080-93. doi: 10.1021/ar200011r. Epub 2011 Jul 26. Acc Chem Res. 2011. PMID: 21786832 Review.
• Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
  Bodey B, Siegel SE, Kaiser HE. Bodey B, et al. Anticancer Res. 1996 Mar-Apr;16(2):661-74. Anticancer Res. 1996. PMID: 8687112 Review.
• Theranostic nanomedicine.
  Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Lammers T, et al. Acc Chem Res. 2011 Oct 18;44(10):1029-38. doi: 10.1021/ar200019c. Epub 2011 May 5. Acc Chem Res. 2011. PMID: 21545096 Review.
• Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
  Muthu MS, Singh S. Muthu MS, et al. Nanomedicine (Lond). 2009 Jan;4(1):105-18. doi: 10.2217/17435889.4.1.105. Nanomedicine (Lond). 2009. PMID: 19093899

Cited by

• Solvent-Free Click-Mechanochemistry for the Preparation of Cancer Cell Targeting Graphene Oxide.
  Rubio N, Mei KC, Klippstein R, Costa PM, Hodgins N, Wang JT, Festy F, Abbate V, Hider RC, Chan KL, Al-Jamal KT. Rubio N, et al. ACS Appl Mater Interfaces. 2015 Sep 2;7(34):18920-3. doi: 10.1021/acsami.5b06250. Epub 2015 Aug 20. ACS Appl Mater Interfaces. 2015. PMID: 26278410 Free PMC article.
• Antibody fragments as nanoparticle targeting ligands: a step in the right direction.
  Richards DA, Maruani A, Chudasama V. Richards DA, et al. Chem Sci. 2017 Jan 1;8(1):63-77. doi: 10.1039/c6sc02403c. Epub 2016 Sep 16. Chem Sci. 2017. PMID: 28451149 Free PMC article.
• Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.
  Hu Y, Liu C, Muyldermans S. Hu Y, et al. Front Immunol. 2017 Nov 2;8:1442. doi: 10.3389/fimmu.2017.01442. eCollection 2017. Front Immunol. 2017. PMID: 29163515 Free PMC article. Review.
• Development of Rous sarcoma Virus-like Particles Displaying hCC49 scFv for Specific Targeted Drug Delivery to Human Colon Carcinoma Cells.
  Kato T, Yui M, Deo VK, Park EY. Kato T, et al. Pharm Res. 2015 Nov;32(11):3699-707. doi: 10.1007/s11095-015-1730-2. Epub 2015 Jun 6. Pharm Res. 2015. PMID: 26047779
• Noncovalent functionalization of carbon nanovectors with an antibody enables targeted drug delivery.
  Berlin JM, Pham TT, Sano D, Mohamedali KA, Marcano DC, Myers JN, Tour JM. Berlin JM, et al. ACS Nano. 2011 Aug 23;5(8):6643-50. doi: 10.1021/nn2021293. Epub 2011 Jul 15. ACS Nano. 2011. PMID: 21736358 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.
  • Taylor & Francis

• Other Literature Sources

  • The Lens - Patent Citations Database